Načítá se...
Colon-specific prodrugs of 4-aminosalicylic acid for inflammatory bowel disease
Despite the advent of biological products, such as anti-tumor necrosis factor-α monoclonal antibodies (infliximab and adalimumab), for treatment of moderate to severe cases of inflammatory bowel disease (IBD), most patients depend upon aminosalicylates as the conventional treatment option. In recent...
Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Baishideng Publishing Group Co., Limited
2014
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3974523/ https://ncbi.nlm.nih.gov/pubmed/24707139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3748/wjg.v20.i13.3564 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|